US resumes shipping antibody treatments that may be ineffective against omicron

The federal government has resumed shipping all three COVID-19 monoclonal antibody treatments to systems across the U.S. despite evidence two of the three may be ineffective in treating omicron, The Washington Post reported Jan. 9.